Oral mucositis associated with targeted therapy and immunotherapy: what s old is new again

Transcription

1 Oral mucositis associated with targeted therapy and immunotherapy: what s old is new again Nathaniel Treister, DMD, DMSc Associate Surgeon Brigham and Women s Hospital Associate Professor Harvard School of Dental Medicine

2 Faculty Disclosure X No, nothing to disclose Yes, please specify: Company Name Honoraria/ Expenses Consulting/ Advisory Board Funded Research Royalties/ Patent Stock Options Ownership/ Equity Position Employee Other (please specify) Midatech Pharma US x Dermtreat ApS x

3 Outline Targeted therapies mtor inhibitors MEK inhibitors PI3K inhibitors an;-vegf TKIs EGFR inhibitors BRAF inhibitors Immune checkpoint inhibitors CTLA4 inhibitors PD-1/PDL-1 inhibitors Hanahan D, Weinberg A. Hallmarks of cancer. Cell 2011;144:646-74

4 mtor inhibitor-associated stoma;;s mtor pathway PI3K/AKT/mTOR frequently upregulated, prolifera;on sirolimus, temsirolimus, everolimus Clinical features aphthous-like ulcers acute onset, days to weeks recurrent, diminish with ;me dose dependent Management topical steroids pallia;ve care dose modifica;on Sonis S, et al. Cancer 2010;116:210 5; Mar;ns F, et al. Oral Oncology 2013;49: ; Shameem R, et al. Cancer Inves;ga;ons 2015;33:70-7

5

6 mias management w/ cor;costeroids Retrospec;ve, open label phase 1/2 trials 17 cancer pa;ents, everolimus/ridaforolimus 10 days median onset (4 25) median pain = 7/10 5 dose reduc;ons, 1 DLT improvement in ~90% w/ steroid therapy topical (15), intralesional (5), systemic (1) pallia;ve treatments w/ limited benefit SWISH trial (n = 92), open label phase 2 advanced HR+/HER2+ breast ca EVE 10 mg/exe 25 mg dexamethasone 0.5 mg/5 ml, 2 min, s/s, QID incidence of grade 2 stoma;;s at 8 wks compared w/ BOLERO-2: 2.4% vs. 33% (p <0.001), 21.2% vs. 67% all grades de Oliveira MA, et al. Oral Oncology 2011;47: ; Rugo H, et al. Lancet Oncol 2017;18:

7 Aphthous stoma;;s w/ other targeted therapies? PI3K inhibitors idelalisib mul;ple phase 1 and 2 studies, no mucosi;s copanlisib phase 1, 6/57 (11%) w/ oral cavity mucosi;s, table, no descrip;on Patnaik A, et al. Annals Oncol 2016;27: MEK inhibitors trame;nib (selume;nib, cobime;nib) mucosi;s / mucosal inflamma;on reported infrequently (2-36%), aphthous-like? no descrip;on Infante J, et al. Lancet Oncol 2012;13: Falchook G, et al. Lancet Oncol 2012;13:782 9 Abdel-Rahman O, et al. Expert Rev Gastroenterol Hepatol 2015;9: acneform rash common Anforth R, et al. Australasian J Dermatol 2014;55:250-4 Taylor B, et al. Nat Rev Cancer 2011;11:541-7

8 MEK inhibitors

9 idelalisib (PI3K inhibitor) MEK+ PI3K inhibitor

10 Oral dysesthesia associated w/ TKIs Mul;-targeted tyrosine kinase inhibitors an;-vegf suni;nib, sorafebib, others Clinical features poorly described in literature normal appearing mucosa oral/tongue sensi;vity, dysesthesia, taste changes associa;on w/ hand-and-foot skin reac;on, increasing severity Management? treat as pain or dysesthesia? diet modifica;ons Kollmannsberger et al. Oncologist 2011;16:543-53; Lee W, et al. Br J Dermatology 2009;161: ; Yuan A, et al. Oral Oncology 2015;51: ; Schmidinger M, et al. Oncologist 2017;22:1-10; Gerendesh B, et al. Oncotargets and Therapy 2017;10:

11 Suni;nib oral toxicity Mucosal sensi;vity most grade 2 <10% required dose reduc;on <1% required discon;nua;on Clinical course 7-14 days aser start/severity increases resolves during 2 wk rest recurs, severity lessens Clinical findings normal single report of bullous mucosi;s (?) Kollmannsberger et al. Oncologist 2011;16:543-53; Mignogna M, et al. Ann Phamacother 2009;43:546-7

12 Immunotherapy-associated oral AEs Immune checkpoint inhibitors block CTLA-4, PD-1/PD-L1; T cell ac;va;on ipilimumab, nivolumab, pembrolizumab Clinical features lichenoid inflamma;on, (bullous pemphigoid ) ~3 months mean onset (cutaneous); highly variable, case reports/series, mul;system possible sicca syndrome (n=4, Hopkins, abrupt onset of severe hypofunc;on, ;meframe variable) GVHD aser allohsct (relapse), poten;ally severe/ refractory acute, overlap, chronic forms combina;on therapy w/ higher rates Management lichenoid topical steroids, +/- modifica;ons sicca pallia;ve, sialogogues, dental early recogni;on, referral Curry J, et al. J Cutan Pathol 2017;44:158-76; Shi V, et al. JAMA Dermatol 2016;152: ; Cappelli LC, et al. Ann Rheum Dis 2017;76:43 50; Haverkos B, et al. Blood. 2017;130:221-8; Sibaud V. Am J Clin Dermatol 2017; Sibaud V, et al. JEADV

13 nivolumab x 2 neoadjuvant head and neck cancer protocol

14 nivolumab-associated lichenoid inflamma;on, managed with topical clobetasol 0.05% solu;on

15 acute GVHD erup;on following 1 st cycle of pembrolizumab for metasta;c colon cancer, s/p RIC allohsct for AML

16 Amitay-Laish I, et al. Dermatologic Therapy 2011;24:386-95; Pileri A, et al. JEADV 2016;30: ; Macdonald J, et al. J Am Acad Dermatol 2015;72:203-18; Hidalgo M, et al. J Clin Oncol 2001;19: ; Hubiche T, et al. Oncologist 2013;18:e16-e17; Gavrilovic I, et al. Oncologist 2012;17:274-8; Boussemart L, et al. Ann Oncol 2013;24:1691-7; Vigarios E, et al. Br J Dermatol 2015;172: Other reported oral toxici;es Ima;nib lichenoid reac;ons, cheili;s, SJS EGF inhibitors mucosi;s, which rarely includes aphthous ulcers, without mucosal changes Vemurafenib mucosal keratosis symptoma;c, gingiva, palate, linea alba, labial regressed on discon;nua;on SCC (lower lip, n = 1) Benign migratory glossi;s/erythema migrans bevacizumab, suni;nib, sorafenib (an;- VEGF?...)

17 s/p allohsct, cgvhd, s/p IL-2, mild symptoms s/p allohsct, cgvhd, de novo, severe symptoms

18 Novel cancer therapies, novel oral toxici;es, but mimic other condi;ons Understand risk, recognize early signs/symptoms Pa;ent educa;on, preven;on, awareness Management depends on correct diagnosis, specialty referral Research opportuni;es abound Summary